FAQ

Availability and quality of data on drug policy and management  of access to reimbursed medicinal products in the United Kingdom, Denmark, Germany, Italy and Poland

Publication date: 2013

Public Health and Governance, 2013, Volume 11, Issue 1, pp. 89 - 99

https://doi.org/10.4467/20842627OZ.14.009.1619

Authors

,
Tomasz Hermanowski
Medical University of Warsaw
ul. Żwirki i Wigury 61, 02-091 Warszawa, Poland
All publications →
,
Sylwia I. Szafraniec-Buryło
National Institute of Public Health, ul. Chocimska 24, 00-791 Warszawa
All publications →
,
Aleksandra N. Krancberg
Medical University of Warsaw
ul. Żwirki i Wigury 61, 02-091 Warszawa, Poland
All publications →
,
Dominika Dulęba
Medical University of Warsaw
ul. Żwirki i Wigury 61, 02-091 Warszawa, Poland
All publications →
Urszula Cegłowska
Medical University of Warsaw
ul. Żwirki i Wigury 61, 02-091 Warszawa, Poland
All publications →

Titles

Availability and quality of data on drug policy and management  of access to reimbursed medicinal products in the United Kingdom, Denmark, Germany, Italy and Poland

Abstract

Objectives: To perform a systematic review, and to verify and define deficiencies in literature data on drug policy and management of access to reimbursed medicinal products in the United Kingdom, Denmark, Germany, Italy and Poland as a source of information intended to be used by government authorities in the decision-making process.
Methods: A systematic review was conducted through database search of Medline, SCOPUS, Embase and Cochrane Library, supplemented by nonsystematic review. The quality of the identified literature was critically appraised.
Results: Information necessary to develop a knowledge base was outline from 121 papers identified through database search. 0.83% of all publications were rated high in all of the assessed categories, i.e. were identified to represent high levels of consistency, coherence, strength and methodological quality.
Conclusions: In the policy decision-making process, concise recommendations based on validated data are more than needed. It is vital to rely on scientific evidence and avoid reports based on simple exchange of information or presenting single-source or unconfirmed data, including expert’s opinion.

References


Information

Information: Public Health and Governance, 2013, Volume 11, Issue 1, pp. 89 - 99

Article type: Original article

Titles:

Polish:

Availability and quality of data on drug policy and management  of access to reimbursed medicinal products in the United Kingdom, Denmark, Germany, Italy and Poland

English:

Availability and quality of data on drug policy and management  of access to reimbursed medicinal products in the United Kingdom, Denmark, Germany, Italy and Poland

Authors

Medical University of Warsaw
ul. Żwirki i Wigury 61, 02-091 Warszawa, Poland

National Institute of Public Health, ul. Chocimska 24, 00-791 Warszawa

Medical University of Warsaw
ul. Żwirki i Wigury 61, 02-091 Warszawa, Poland

Medical University of Warsaw
ul. Żwirki i Wigury 61, 02-091 Warszawa, Poland

Medical University of Warsaw
ul. Żwirki i Wigury 61, 02-091 Warszawa, Poland

Published at: 2013

Article status: Open

Licence: None

Percentage share of authors:

Tomasz Hermanowski (Author) - 20%
Sylwia I. Szafraniec-Buryło (Author) - 20%
Aleksandra N. Krancberg (Author) - 20%
Dominika Dulęba (Author) - 20%
Urszula Cegłowska (Author) - 20%

Article corrections:

-

Publication languages:

English